TriWest Research Associates

# *CURRICULUM VITAE*

| | | | |
|---|---|---|---|
| **SIGNATURE:** | | **DATE:** | 10 July 14 |
| **NAME:**<br>**TITLE:** | Arthur R. Mabaquiao, MD<br>Principal Investigator | **DATE UPDATED:** | July 2014 |

**RESEARCH SITE ADDRESS & PHONE:**

| **Main Office** | **Contact Info:** |
|---|---|
| TriWest Research Associates, LLC<br>300 South Pierce Street, Suite 201<br>El Cajon, CA 92020 | Office: (619) 334-4735<br>Fax: (619) 334-4769<br>Email: drmabaquiao@triwestresearch.com |

**EDUCATION/TRAINING:**

| INSTITUTION AND LOCATION | DEGREE *(if applicable)* | YEAR(s) | FIELD OF STUDY |
|---|---|---|---|
| University of California Irvine<br>UCI Medical Center, Orange, CA<br>VA Medical Center, Long Beach, CA | | 1998-2000 | Rheumatology Fellowship |
| University of California Irvine<br>UCI Medical Center, Orange, CA<br>VA Medical Center, Long Beach, CA | | 1995-1998 | Internal Medicine Residency |
| Loma Linda University School of Medicine<br>Loma Linda, CA | | 1991-1995 | Medical Doctor |
| Loma Linda University: School of Allied Health Professions<br>Loma Linda, CA | Bachelor of Science | 1985 - 1990 | Physical Therapy |

**BOARD CERTIFIED:**

| BOARD CERTIFIED/ELIGIBLE | YEAR(s) | SPECIALTY |
|---|---|---|
| Board Certified | 2010 | Rheumatology |
| Board Certified | 2009 | Internal Medicine |

**POSITIONS AND EMPLOYMENT:**

| | |
|---|---|
| 2009 - Present | Principal Investigator, TriWest Research Associates LLC, El Cajon, CA |

| | |
|---|---|
| 2009-Present | Joint Assessor, TriWest Research Associates LLC, El Cajon, CA |
| 2005 - Present | Cabrillo Center for Rheumatic Disease, El Cajon, CA |
| 2013-Present | Medical Director, Cabrillo Infusion, El Cajon, CA |
| 2002 - 2005 | Physician, San Diego Arthritis Medical Clinic, San Diego, CA |
| 2001 - 2002 | Assistant Professor, LLU Physicians Medical Group, Inc., Loma Linda, CA |
| 2000 - 2001 | Assistant Clinical Professor, University of California Irvine, Irvine, CA |
| 1998 - 1999 | Internal Medicine Hospitalist, Harriman Jones Medical Group, Long Beach, CA |
| 1990 - 1991 | Physical Therapist, Riverside Medical Clinic, Riverside, CA |
| 1990 - 1991 | Physical Therapist, Parkview Community Hospital, Riverside, CA |

## CLINICAL RESEARCH EXPERIENCE:

Pfizer Pharmaceuticals: XXXX A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of XXXX in Patients with Osteoarthritis of the Knee

Pfizer Pharmaceuticals: XXXX A Phase 3. Multi-Center, Randomized, Double blind, Controlled study of the long term analgesic efficacy of XXXX alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDS) versus NSAIDS alone in patients with Osteoarthritis of the knee or hip

Ferring Pharmaceuticals:.XXXX A Phase 2, 26 week, Double blind, Randomized, Placebo controlled trial of the efficacy and safety of single XXXX injection 1.2% sodium Hyaluronate for treatment of painful Osteoarthritis of the knee, with optional 26 week open-label extension

Regeneron Pharmaceuticals: XXXX A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel-Group Study of the safety and efficacy of subcutaneously administered XXXX in patients with Sciatic Pain

Endo Pharmaceuticals, Inc: A Phase 2b, Randomized, Double-Blind, Two-Arm, Multi-Center, Placebo-Controlled, Study to Asses the Efficacy and Safety of XXXX in Subjects with Moderate to Severe Chronic Low Back Pain

King Pharmaceuticals Research and Development, Inc: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of XXXX (XXXX) in Patients with Chronic Low Back Pain

Velvet: (Veltuzumab various doses exploratory trial), a Randomized, Double-Blind, Placebo-controlled, Multicenter, Multinational Phase II Dose Range Fining Trial in Subjects with Moderate to Severe Rheumatoid Arthritis Insufficiently Controlled with Either Methotrexate alone or Methotrexate Plus Anti-Tumor Necrosis Factor Biological Treatment, Comparing 3 Different Subcutaneous Doses of anti-CD20 Monoclonal Antibody Veltuzumab to Placebo as an Add-On Therapy to Methotrexate

UCB: A Phase 4, Multicenter, Randomized, 52-week Study to Evaluate the Routine Assessment of Patient Index Data (Rapid3) Compared to the Clinical Disease Activity Index (CDAI) to Prospectively Predict Treatment Success at 52 weeks Based on a Treatment Decision at Week 12 in Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Certolizumab Pegol (CZP)

Novartis Motion: Multinational, prospective, Observational study to characterize and assess the burden of refractory gouty arthritis on patients over one year

Eli Lilly and Company: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy

Eli Lilly and Company: A Phase 3b, Multicenter, Open-Label, Study to Evaluate the Long-Term Safety and Efficacy of XXXX in Patients with Rheumatoid Arthritis (RA)

Eli Lilly and Company: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response o one or more TNF-ά InhibitorsEli Lilly and Company: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of XXXX in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

Biocryst Pharmaceuticals: A Randomized, Dose-Response Study of the Safety and Efficacy of Oral XXXX Added to Allopurinol in Subjects with Gout Who Have Not Adequately Responded to Allopurinol Monotherapy

Vertex: 12-week, double blind, randomized, parallel-group, placebo controlled study of 4 doses of XXXX in subjects with active rheumatoid arthritis. Phase 2a

Celgene Pharmaceuticals: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Two Doses of XXXX ( XXXX) in Subjects with Active Rheumatoid Arthritis Who Have had an Inadequate Response to Methotrexate

Eli Lilly and Company: A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of XXXX (an Anti-IL-17 Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy

UCB: A Multicenter, Single-Blind, Randomized Parallel-Group Study to Assess the Short-and-Long-Term Efficacy of XXXX plus Methotrexate Compared with Adalmumab plus Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate

Merck Sharp & Dohme Corp.: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of XXXX in Subjects with Active Rheumatoid Arthritis and inadequate Response or Intolerance to Anti-TNF-a Therapy

Diamyd Inc: A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Impact of XXXX in Subjects with Intractable Pain due to Malignancy

Purdue: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-Label Run – in to Assess the Efficacy and Safety of XXXX Tablets to 20 to 120 mg Once daily in Subjects with Moderate to Severe Chronic Low Back Pain

Purdue Pharma: An Open-label, Multicenter Study to Assess the Long -term Safety of XXXX Tablets 20 to 120 mg Once-daily in Subjects with Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain

Purdue Pharma L.P.: A Randomized, Double-blind, Placebo-controlled, Multicenter Trial with an Enriched Study Design to Assess the Efficacy and Safety of XXXX/XXXX Controlled-release Tablets

(OXN) Compared to Placebo in Opioid-experienced Subjects with Moderate to Severe Pain due to Chronic Low Back Pain who Require Around-the-clock Opioid Therapy

Purdue Pharma L.P.: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXXX/XXXX Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) In Opioid-experienced Subjects with Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy

Purdue Pharma L.P.: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXXX/XXXX Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) IN Opioid-experienced Subjects with Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy

Abbot Laboratories: A Global Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Study Comparing the Analgesic Efficacy and Safety of XXXX to Placebo in Subjects with Osteoarthritis Pain of the Knee

Covidien: Phase 3 - An Open Label Safety Study of XXXX in Subjects With Osteoarthritis or Chronic Low Back Pain

Genentech Inc: A multicenter, open-label, single-arm study to evaluate the safety of administering XXXX at a more rapid infusion rate in patients with rheumatoid arthritis (Phase IV)

Genentech Inc: A non-interventional, multi-site retrospective chart review study in patients with Rheumatoid Arthritis

Eli Lilly: A Phase 3b, multicenter, open-label study to evaluate the long term safety and efficacy of subcutaneous XXXX in patients with Systemic Lupus Erythematous (SLE) (ILLUMINATE-X)

AstraZeneca: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

Antares Pharma, Inc: A Phase 2, Multi-Center, Open-Label, Single-Dose, Single-Arm, In-Clinic Study to Evaluate the Actual Human Use of Methotrexate Subcutaneously Administered via the VIBEX™ MTX-Auto-Injector Device in Adult Patients with Rheumatoid Arthritis

Auxilium Pharmaceuticals: A Phase 2a, Open-Label, Dose-Ranging Study of the Safety and Effectiveness of XXXX for the treatment of Adhesive capsulitis of the shoulder

Cephalon; A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety and Efficacy of XXXX Administered at Single Doses of 0.5, 1, 3, 6, or 12 mg by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation

Furiex: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of XXXX in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome

Abbott: A Multicenter Study of the Prevalence of Axial Spondyloarthritis (SpA) in the United States among Subjects with Chronic Back Pain and Other SpA-Related Features

Eli Lilly and Company: Phase 3, Psychometric Validation of Performance Based Measures for Use with Hip Fracture and Elective Hip and Knee Replacement Populations

Janssen Research & Development: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of XXXX (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis despite DMARD Therapy

Janssen Research & Development: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of XXXX (sirukumab), A Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF-a Therapy

Eli Lilly: Psychometric Validation of Performance Based Measures for Use with Hip Fracture and Elective Hip and Knee Replacement Populations

Human Genome Sciences: A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Cubist Pharmaceuticals, Inc.: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of XXXX For the Treatment of Opioid-Induced Constipation In Adults Taking Opioid Therapy For Chronic Non-Cancer Pain

Takeda: A Multicenter, randomized, active control, phase 3b study to evaluate the cardiovascular safety of XXXX and Allopurinol in subjects with Gout and cardiovascular comorbidities

Novo Nordisk Inc.: A Randomized, double-blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of XXXX, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to anti-TNf-a biologics

Novo Nordisk Inc.: A Randomized, double-blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of XXXX, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to Methotrexate

Takeda: A Multicenter, Randomized, Active-Control, Study to evaluate the cardiovascular safety and efficacy of XXXX and XXXX in subjects with Cardiovascular Comorbidities, Hyperuricemia, and Gout. Phase 3b

Eli Lilly and Company: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous XXXX in Patients with Systemic Lupus Erythematosus (SLE)

UCB: A Multicenter, Single-Blind, Randomized Parallel-Group Study to Assess the Short-and-Long-Term Efficacy of XXXX plus Methotrexate Compared with Adalmumab plus Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate

Bayer: A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral XXXX compared to vitamin K antagonist (VKA) for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion (Z)

Forest Research Institute, Inc: A Randomized, Double-Blind, Placebo-and-Active-Controlled Study to Evaluate the Safety and Efficacy of XXXX in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

QMED: A Multicenter, Randomized, Double Blind, Saline Controlled Study of a Single Injection of XXXX versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated with Osteoarthritis of the Knee

Boehringer Ingelgeim: A randomized, double-blind, parallel arm, multiple dose, active comparator trial, efficacy, Pharmacokinetics, and safety of XXXX versus rituximab in patients with moderately to severely active rheumatoid arthritis

Astra Zeneca: Prospective observational study, estimate the rate of inadequate response to laxatives (LIR) in a cohort of patients with OIC

Sativex: A double blind, randomized, placebo-controlled, parallel group study of XXXX oromucosal spray , as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy

Sativex: A multicenter, non-comparative, open-label extension study to assess the long term safety of XXXX oromucosal spray as adjunctive therapy in patients with uncontrolled persistent chronic cancer related pain

Mannkind Corporation: A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of XXXX Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects with Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12-month Treatment Period with a 2-month Follow-up

Cubist: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of XXXX for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy For Chronic Non-Cancer Pain

Theravance: A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of XXXX in Subjects with Fibromyalgia (FM)

Takeda: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral XXXX and 50 mg Compared to Placebo When Used in Combination with Sitagliptin in Subjects with Type 2 Diabetes

Human Genome Sciences: A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Janssen: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of XXXX (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

Pfizer Inc: Phase 3 Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group evaluation of the efficacy, safety, and tolerability of XXXX, in reducing the occurrence of major cardiovascular events in high risk subjects

Pfizer Inc: Phase 3 Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group evaluation of the efficacy, safety, and tolerability of XXXX, in reducing the occurrence of major cardiovascular events in high risk subjects

Santarus: A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of XXXX in Patients

with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s)

Regeneron Pharmaceuticals: A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel-Group Study of the safety and efficacy of subcutaneously administered XXXX in patients with Sciatic Pain

Eli Lilly and Company: Pharmacokinetic Evaluations of XXXX Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients with Systemic Lupus Erythematosus

Novartis: A Randomized, Double-Blind, Placebo-and active-controlled Study of XXXX to Demonstrate the Efficacy at 24 Weeks and to assess the safety, tolerability and long term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents

HGS: A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™

Auxilium Pharmaceuticals: A Phase 2b, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of XXXXXX for the Treatment of Adhesive Capsulitis of the Shoulder

Teva: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of XXXX Extended-Release Tablets at 30mto 90 mg Every 12 Hours of Relief of Moderate to Severe Pain in Patients with Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time (Phase 3)

Amgen Inc.: An Open-Label, Single-Arm Extension Study To Evaluate The Long-Term Safety And Efficacy Of XXXX In Subjects With Moderate To Severe Rheumatoid Arthritis

Bioventus: A Multicenter, Randomized, Double-Blind, Parallel, Active Controlled Non-Inferiority Clinical Trial Comparing Three Weekly Intra-Articular Injections of XXXX versus Three Weekly Intra-Articular Injections Of XXXXFor Treatment Of Osteoarthritis Pain Of The Knee

Flexion: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of XXXX for the Treatment of Pain in Patients with Osteoarthritis of the Knee

Kowa Research Institute, Inc.: A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Compared With Placebo for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain

Novo Nordisk: A Randomized, double-blind, cross-over trial comparing the safety and efficacy of insulin XXX and insulin XXXX, with or without OADs in subjects with type 2 diabetes

CymaBay Therapeutics: A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Fidia Farmaceutici S.p.A.: A multic-center, parallel, double-blind, randomized, placebo-controlled study to evaluate the safety and effectiveness of XXXX, a new viscoelastic hydrogel, for the treatment of osteoarthritis of the knee

Samumed: A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Novartis: A 56-week, randomized, multi-center, double-blind, placebo-controlled, phase IIa/IIb study to evaluate the safety and efficacy of i.v. bimagrumab on total lean body mass and physical performance in patients after surgical treatment of hip fracture